Suggested remit: To appraise the clinical and cost effectiveness of avatrombopag within its marketing authorisation for treating chemotherapy-induced thrombocytopenia in non-haematological cancers.
Following on from information provided to NICE by the company in August 2022, the appraisal of Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Decision Selected
Process TA
ID number 3837

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
31 August 2023 Discontinued. Following on from information provided to NICE by the company in August 2022, the appraisal of Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
04 August 2022 Suspended. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
03 February 2021 - 03 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 February 2021 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal. The company that market avatrombopag has advised NICE that they are currently not pursuing a licence in the UK for this product for this indication. In light of this information, NICE will not be progressing with the scoping exercise. The consultation on the draft scope will now close. Please accept our apologies for any inconvenience.

For further information on our processes and methods, please see our CHTE processes and methods manual